Wall Street analysts’ average price target implies 97.3% upside for AbCellera Biologics (ABCL), with the article also noting a positive trend in earnings estimate revisions. The piece is fundamentally supportive but based on analyst sentiment rather than operating results, so the likely market impact is limited.
Wall Street analysts’ average price target implies 97.3% upside for AbCellera Biologics (ABCL), with the article also noting a positive trend in earnings estimate revisions. The piece is fundamentally supportive but based on analyst sentiment rather than operating results, so the likely market impact is limited.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
